Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:60061
Name primary cutaneous T-cell non-Hodgkin lymphoma
Definition A peripheral T-cell lymphoma that has_material_basis_in a mutation of T cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma mature T-cell and NK-cell lymphoma peripheral T-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated USA 0
NCT01196208 Expanded access Brentuximab vedotin A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 No longer available USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BGR | BEL | AUS 2
NCT01637090 Phase II Everolimus Everolimus in Treating Cutaneous T-cell Lymphoma Terminated USA 0
NCT01843998 Phase II Sirolimus Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) Withdrawn USA 0
NCT01871727 Phase III E7777 A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma Completed USA | AUS 1
NCT01902225 Phase I Pegylated liposomal doxorubicin + Romidepsin Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Completed USA 0
NCT01976585 Phase Ib/II CDX-301 + Poly ICLC In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy Completed USA 0
NCT02192021 Phase I Doxorubicin Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Completed USA 0
NCT02512497 Phase I Romidepsin Busulfan + Fludarabine + Romidepsin Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Active, not recruiting USA 0
NCT02556463 Phase I MEDI9197 Durvalumab + MEDI9197 A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors Terminated USA | FRA | CAN 0
NCT02567656 Phase I Tenalisib Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma Completed USA 0
NCT02616965 Phase I Brentuximab vedotin + Romidepsin A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Active, not recruiting USA 0
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Completed USA 0
NCT02689453 Phase I Alemtuzumab + rhIL-15 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Completed USA 0
NCT02974647 Phase II Ruxolitinib Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma Recruiting USA 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03011814 Phase Ib/II Durvalumab Durvalumab + Lenalidomide Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Active, not recruiting USA 0
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Recruiting USA 0
NCT03235869 Phase I Durvalumab Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma Withdrawn USA 0
NCT03239392 Phase Ib/II BNZ-1 A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL Completed USA 0
NCT03240211 Phase I Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab + Pralatrexate Decitabine + Pembrolizumab Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Recruiting USA 0
NCT03292406 Phase II CD11301 A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (CTCL) Completed USA | FRA | DEU 0
NCT03385226 Phase II Pembrolizumab A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) (PORT) Active, not recruiting GBR 0
NCT03409432 Phase II Brentuximab vedotin + Lenalidomide Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Active, not recruiting USA 0
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Terminated USA 0
NCT03829540 Phase I CD4CAR CD4CAR for CD4+ Leukemia and Lymphoma Recruiting USA 0
NCT03900442 Phase I GGTI-2418 Phase 1 Study of PTX-100 in Patients With Advanced Malignancies Unknown status AUS 0
NCT04136275 Phase I Anti-CD37 CAR T cells CAR-37 T Cells In Hematologic Malignancies Completed USA 0
NCT04171791 Phase I Venetoclax A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) Completed USA 0
NCT04234048 Phase I Fenretinide Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Recruiting USA 0
NCT04703192 Phase II DS-3201b Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 3
NCT04747236 Phase II Pralatrexate Belinostat Azacitidine + Romidepsin Gemcitabine Romidepsin A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) Recruiting USA 0
NCT04752826 Phase Ib/II BI-1808 + Pembrolizumab BI-1808 BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) Recruiting USA | SWE | HUN | GBR | DNK 1
NCT04774068 Phase I Romidepsin Parsaclisib + Romidepsin Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Active, not recruiting USA 0
NCT04848064 Phase I Cyclophosphamide + Fludarabine Mogamulizumab Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Recruiting USA 0
NCT04858256 Phase II Pacritinib Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms Recruiting USA 0
NCT05010005 Phase I Duvelisib + Ruxolitinib A Study of Ruxolitinib and Duvelisib in People With Lymphoma Active, not recruiting USA 0
NCT05079282 Phase I ONO-4685 Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Recruiting ITA | FRA | ESP 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05569057 Phase I SIM1811-03 A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma Recruiting USA 0
NCT05879458 Phase II Ritlecitinib Ritlecitinib in CTCL Recruiting USA 0
NCT05956041 Phase II Mogamulizumab + Pembrolizumab Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas Recruiting USA 0
NCT05967416 Phase I SIRPant-M Phase 1, Open-Label Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Recruiting USA 0
NCT06120504 Phase I SGN-35T A Safety Study of SGN-35T in Adults With Advanced Cancers Recruiting USA | GBR | ESP | DNK | CAN 0